Incyte Corporation (INCY) - News Archive

Incyte Set to Shine at ASH Annual Meeting 2025 with Over 50 Accepted s Focused on Advancements in Hematology Incyte Corporation (Nasdaq: INCY), a leading biopharmaceutical company, has announced the acceptance of over 5...

Wilmington, Delaware Incyte Corporation (Nasdaq: INCY) has unveiled pivotal clinical results from the Phase 1 study of its bispecific antibody TGFR2PD-1 (INCA33890), aimed at targeting advanced colorectal cancer, alongs...

Incyte s Advancements in Cancer Treatment: Promising Phase 3 Data for Retifanlimab and Strong Revenue Growth Amidst Competitive ChallengesIn the ever-evolving landscape of oncology, few developments spark as much intere...

Incyte to Unveil Groundbreaking Early-Phase Oncology Research at the 2025 AACR Annual Meeting WILMINGTON, Delaware Incyte Corporation (Nasdaq: INCY) has announced plans to reveal significant new findings in early-phase...

Wilmington, DE Incyte Corporation (Nasdaq: INCY) has announced its participation in the 2025 Annual Meeting of the American Academy of Dermatology (AAD), scheduled from March 7 to March 11 in Orlando, USA. The event pro...

Incyte Unveils Pioneering Oncology and Dermatology Data at Major 2024 Medical Conferences By , CSIMarket.com WILMINGTON, Del. Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company famed for its innovative appro...

Incyte to Showcase Cutting-Edge Dermatology and Oncology Data at 2024 Medical Conferences Wilmington, Delaware Incyte Corporation (Nasdaq: INCY) is set to present a comprehensive range of new data from its dermatology a...

WILMINGTON, Del. Incyte (Nasdaq: INCY), a global biopharmaceutical company, has announced the upcoming presentation of significant new data from its dermatology portfolio at the prestigious European Academy of Dermatolo...

Incyte Corporation s recent presentation of promising data from its ongoing clinical trials has highlighted a potential breakthrough in the treatment of squamous cell anal carcinoma (SCAC). The investigational drug, Ret...

Promising Developments in Oncological Therapies: Incyte s CDK2 Inhibitor Shows Early Clinical Activity WILMINGTON, Del. Incyte Corporation (Nasdaq: INCY) has announced promising early clinical data for its CDK2 inhibito...

Incyte Corporation (Nasdaq: INCY) is a biopharmaceutical company that has made significant strides in the field of oncology, with its innovative therapies aimed at helping patients who lack sufficient treatment options....

Wilmington, Delaware, October 2023 Incyte Corporation (Nasdaq: INCY) has announced its intention to present significant findings from its oncology portfolio at the upcoming European Society for Medical Oncology (ESMO) C...

Incyte Delivers Promising News: Tafasitamab Shows Efficacy in Phase 3 Study for Relapsed or Refractory LymphomaIn a significant development for the oncology community, Incyte Corporation (NASDAQ: INCY) announced encoura...

FDA Approves Niktimvo for Treatment of Chronic Graft-Versus-Host Disease WILMINGTON, Del. and WALTHAM, Mass. Incyte (Nasdaq: INCY) and Syndax Pharmaceuticals (Nasdaq: SNDX) announced today that the U.S. Food and Drug Ad...

Incyte, a leading biopharmaceutical company specializing in oncology, has recently announced that it will be presenting data from its oncology portfolio at two major medical conferences in 2024. The American Society of...

Incyte Reveals Promising Oncology Data at ASCO 2024 and EHA2024 CongressWilmington, Delaware - Incyte (Nasdaq: INCY), a leading biopharmaceutical company, announced today that multiple abstracts highlighting data from i...